Second European Stroke Prevention Study (ESPS 2): clinical and pharmacological implications.
Vane
J R
JR
Meade
T W
TW
D001241:Aspirin / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000517:prevention & control*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005060:Europe; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin